NCT01722968View on ClinicalTrials.gov

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2018

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab

15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly

DRUG

Paclitaxel

80mg/m2 iv weekly

Trial Locations (1)

17176

Karolinska University Hospital, Solna

All Listed Sponsors
lead

Theodoros Foukakis

OTHER

NCT01722968 - A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | Biotech Hunter | Biotech Hunter